2025 -  WEEK 2 - What's New in RWE Research

 

 

  1. Multiple Perspectives on the Need for Real-World Evidence to Inform Regulatory and Health Technology Assessment Decision-Making: Scoping Review and Stakeholder Interviews. Jansen MS, Dekkers OM, le Cessie S, Hooft L, Gardarsdottir H, de Boer A, Groenwold RHH. Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70074. https://pubmed.ncbi.nlm.nih.gov/39777765/

 

  1. A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines. Zong J, Rojubally A, Pan X, Wolf B, Greenfeder S, Upton A, Gdovin Bergeson J. Value Health. 2025 Jan;28(1):31-41. https://pubmed.ncbi.nlm.nih.gov/39393564/

 

  1. Health Care Resource Use and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Polypharmacy Patients With Obesity. Alberts M, He J, Kharat A, Pericone CD, Ashton V. J Am Heart Assoc. 2025 Jan 10:e036401. https://pubmed.ncbi.nlm.nih.gov/39791405/

 

  1. Long-Term Weight Loss Outcomes in a Virtual Weight Care Clinic Prescribing a Broad Range of Medications Alongside Behavior Change. Clark JM, Smith BJ, Juusola JL, Kumar RB.Obes Sci Pract. 2025 Jan 8;11(1):e70036. https://pubmed.ncbi.nlm.nih.gov/39790443/

 

  1. Real-world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA-elderly). Fiore V, Carbotta G, Barraco S, Falasca P, Aricò CN, Barucca A.Diabetes Obes Metab. 2025 Jan 10. https://pubmed.ncbi.nlm.nih.gov/39789997/

 

  1. Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain. Hasaligil A, Munro V, Strunz-McKendry T, Wang-Silvanto J, Milloy N, Unsworth M, De Santis M. Future Oncol. 2025 Jan 10:1-10. https://pubmed.ncbi.nlm.nih.gov/39789976/

 

  1. Guidance for an Effective Approach to Integrated Evidence Planning in a Dynamic World. Grueger J, Srikant V.Clin Pharmacol Ther. 2025 Jan 9. Review. https://pubmed.ncbi.nlm.nih.gov/39789863/

 

  1. Objective study validity diagnostics: a framework requiring pre-specified, empirical verification to increase trust in the reliability of real-world evidence. Conover MM, Ryan PB, Chen Y, Suchard MA, Hripcsak G, Schuemie MJ. J Am Med Inform Assoc. 2025 Jan 10:ocae317. https://pubmed.ncbi.nlm.nih.gov/39789670/

 

  1. Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes. Fésü D, Bárczi E, Csoma B, Polivka L, Boga M, Horváth G, Varga JT, Sebők S, Müller V.BMC Infect Dis. 2025 Jan 9;25(1):43. https://pubmed.ncbi.nlm.nih.gov/39789448/

 

  1. A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib. Wang H, Li J, Zhu X, Wang R, Wan Y.Sci Rep. 2025 Jan 9;15(1):1425. https://pubmed.ncbi.nlm.nih.gov/39789316/

 

  1. Incidence of Severe Illness in Pediatric Influenza Outpatients Treated with Baloxavir or Neuraminidase Inhibitors. Miyairi I, Miyazawa S, Takahashi Y, Kojima S, Kitanishi Y, Ogura E.J Infect Chemother. 2025 Jan 7:102606. https://pubmed.ncbi.nlm.nih.gov/39788370/

 

  1. Everolimus with or without mycophenolate mofetil for GVHD prophylaxis after allogeneic HSCT in children with acute kidney injury - a single-center retrospective analysis. Zirngibl F, Gebert P, Materne B, Launspach M, Künkele A, Hundsdoerfer P, Cyrull S, Deubzer HE, Kühl JS, Eggert A, Lang P, Oevermann L, von Stackelberg A, Schulte JH.Transplant Cell Ther. 2025 Jan 7:S2666-6367(25)00003-X. https://pubmed.ncbi.nlm.nih.gov/39788293/

 

  1. Evaluating ADHD medication trial representativeness: a Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individuals. Garcia-Argibay M, Chang Z, Brikell I, Kuja-Halkola R, D'Onofrio BM, Lichtenstein P, Newcorn JH, Faraone SV, Larsson H, Cortese S.Lancet Psychiatry. 2025 Jan 6:S2215-0366(24)00396-1. https://pubmed.ncbi.nlm.nih.gov/39788146/

 

  1. Twenty-Five Years of Evolution and Hurdles in Electronic Health Records and Interoperability in Medical Research: Comprehensive Review. Shen Y, Yu J, Zhou J, Hu G.J Med Internet Res. 2025 Jan 9;27:e59024. https://pubmed.ncbi.nlm.nih.gov/39787599/

 

  1. A Real-World Approach to Trifarotene Treatment in Patients with Acne and Acne Sequelae Based on the Experience of the Italian Acne Board. Annunziata MC, Barbareschi M, Bettoli V, Dall'Oglio F, Micali G, Monfrecola G, Skroza N, Tretti Clementoni M, Veraldi S.Dermatol Ther (Heidelb). 2025 Jan 9. https://pubmed.ncbi.nlm.nih.gov/39786713/

 

  1. Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes. Del Prete M, Gavazzi L, Disoteo OE, Vignati F, Di Sacco G, Muratori F.Eat Weight Disord. 2025 Jan 9;30(1):2. https://pubmed.ncbi.nlm.nih.gov/39786599/

 

  1. Leveraging Natural Language Processing and Machine Learning Methods for Adverse Drug Event Detection in Electronic Health/Medical Records: A Scoping Review. Golder S, Xu D, O'Connor K, Wang Y, Batra M, Hernandez GG. Drug Saf. 2025 Jan 9. Review. https://pubmed.ncbi.nlm.nih.gov/39786481/

 

  1. Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study. Slotman E, Pape M, van Laarhoven HWM, Pouw RE, van der Linden YM, Verhoeven RHA, Siesling S, Fransen HP, Raijmakers NJH.Int J Cancer. 2025 Jan 9. https://pubmed.ncbi.nlm.nih.gov/39786196/

 

  1. Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study. Mountzios G, Lampaki S, Linardou H, Georgoulias V, Mavroudis D, Anevlavis S, Charpidou A, Lykka M, Spyratos D, Sarris EG, Somarakis A, Papista C, Glentis A, Nikolaou A, Paparepa Z, Papageorgiou F, Syrigos KN.Future Oncol. 2025 Jan 9:1-16. https://pubmed.ncbi.nlm.nih.gov/39785129/

 

  1. Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a "real-world" setting. Smith SE, McCoy-Gross K, Malcolm A, Oranski J, Markway JW, Miller TM, Bucelli RC.Ann Clin Transl Neurol. 2025 Jan 9. https://pubmed.ncbi.nlm.nih.gov/39783194/

 

  1. Real-world effectiveness of intravenous belimumab in adults with systemic lupus erythematosus: results of the observational OBSErve study in the Russian Federation. Lila AM, Aseeva EA, Zagrebneva AI, Vinogradova IB, Samigullina RR, Khamashta M, Elfishawy T, Teichman L, Dos Santos D, Queiroz J, Kniazeva LA, Noibi S. BMC Rheumatol. 2025 Jan 8;9(1):4 https://pubmed.ncbi.nlm.nih.gov/39780259/

 

  1. Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS). Gao H, Zhai X, Hu Y, Wu H.Sci Rep. 2025 Jan 8;15(1):1302. https://pubmed.ncbi.nlm.nih.gov/39779872/

 

  1. Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study. Huang Z, Liao TC, Chuang AT, Shao SC, Lange J, Lin TC, Kim M, Lai EC.Osteoporos Int. 2025 Jan 8. https://pubmed.ncbi.nlm.nih.gov/39777487/

 

  1. Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pyloritreatment in elderly patients. Gao W, Li JW, Ye H, Zhang XZ, Liu JX, Cheng H.World J Gastroenterol. 2025 Jan 7;31(1):101463 https://pubmed.ncbi.nlm.nih.gov/39777248/

 

  1. Weight loss and body composition after compounded semaglutide treatment in a real world setting. Chun E, Alexandra Siojo, Rivera D, Reyna K, Legere H, Joseph R, Pojednic R.Diabetes Obes Metab. 2025 Jan 7. https://pubmed.ncbi.nlm.nih.gov/39776038/

 

  1. US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Eugeni P, Rooney ME, Saikali NP, Niu Z, Driessen MT, Krasenbaum LJ, Carr K, Seminerio MJ, McVige JW.Adv Ther. 2025 Jan 8. https://pubmed.ncbi.nlm.nih.gov/39775579/

 

  1. Prevalence of urinary tract infections in women with vulvovaginal atrophy and the impact of vaginal prasterone on the rate of urinary tract infections. Rubin R, Sanaee M, Yee A, Moyneur E, Dea K, Dury AY.Menopause. 2025 Jan 7. https://pubmed.ncbi.nlm.nih.gov/39774900/

 

  1. Utilization and outcomes of life-supporting interventions in older ICU patients in Japan: a nationwide registry study. Shiotsuka J, Masuyama T, Uchino S, Sasabuchi Y, Suzuki R, Ono S, Yoshinaga K, Iizuka Y, Sanui M.Intensive Care Med. 2025 Jan 7. https://pubmed.ncbi.nlm.nih.gov/39774864/

 

  1. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort. Yokomaku Y, Teruya K, Watanabe D, Endo T, Minami R, Taguchi N, Cassidy T, Marongiu A, Thorpe D, Shirasaka T, Oka S.PLoS One. 2025 Jan 8;20(1):e0313338. https://pubmed.ncbi.nlm.nih.gov/39774438/

 

  1. Activity impairment, work productivity, health-related quality-of-life, and costs associated with uncomplicated urinary tract infection among females in Germany. O'Brien M, Marijam A, Mitrani-Gold FS, Terry L, Taylor-Stokes G, Joshi AV. PLoS One. 2025 Jan 7;20(1):e0313752. https://pubmed.ncbi.nlm.nih.gov/39774336/

 

  1. Real-world effectiveness of hemodialysis modalities: a retrospective cohort study. Zhang Y, Winter A, Ferreras BA, Carioni P, Arkossy O, Anger M, Kossmann R, Usvyat LA, Stuard S, Maddux FW.BMC Nephrol. 2025 Jan 7;26(1):9. https://pubmed.ncbi.nlm.nih.gov/39773397/

 

  1. Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD using US nationwide real-world data. Wanner C, Schuchhardt J, Bauer C, Brinker M, Kleinjung F, Vaitsiakhovich T.BMC Nephrol. 2025 Jan 7;26(1):8. https://pubmed.ncbi.nlm.nih.gov/39773376/

 

  1. A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy. Calabria S, Ronconi G, Dondi L, Dondi L, Dell'anno I, Piccinni C, Esposito I, Addesi A, Gnesi M, Cosentino N, D'Amelio M, Martini N, Maggioni AP. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan 8. https://pubmed.ncbi.nlm.nih.gov/39773081/

 

  1. Inequities in the Use of Disease-Modifying Therapy Among Adults Living With Multiple Sclerosis in Urban and Rural Areas in Alberta, Canada. Balcom EF, Mccombe JA, Kate MP, Vu K, Martins KJB, Aponte-Hao S, Richer L, Williamson T, Klarenbach SW, Smyth PS.Neurology. 2025 Feb 11;104(3):e210251. https://pubmed.ncbi.nlm.nih.gov/39772662/

 

  1. Evidence-based Interventions for Youth With Concurrent Mental Health and Substance Use Disorders: A Scoping Review: Interventions fondées sur des données probantes pour les jeunes atteints de troubles concomitants de santé mentale et liés à l'usage de substances psychoactives : une étude de la portée. Marshall T, Reeson M, Loverock A, Lewis AE, King I, Ilyas R, Dixon CC, Viste D, Azer B, Chow E, Safi F, Kennedy M, Abba-Aji A, Greenshaw AJ.Can J Psychiatry. 2025 Jan 6:7067437241300957. https://pubmed.ncbi.nlm.nih.gov/39763221/

 

  1. Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort study. Hopkins R, Young KG, Thomas NJ, Jones AG, Hattersley AT, Shields BM, Dennis JM, McGovern AP; MASTERMIND consortium.Diabetes Obes Metab. 2025 Jan 6. https://pubmed.ncbi.nlm.nih.gov/39762966/

 

  1. Real-world evaluation of physiotherapist-led exercise prehabilitation and rehabilitation during autologous stem cell transplantation in myeloma: a single-centre experience. Land J, Luong MK, Longden A, Rabin N, Kyriakou C, Sive J, Fisher A, Yong K, McCourt O.BMJ Open Qual. 2025 Jan 6;14(1):e002936. https://pubmed.ncbi.nlm.nih.gov/39762061/

 

  1. A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries. Alfalasi A, Ameen A, Al Lafi A, El Gendi A, Saad W, Ismail A, Al Naeem A, Goturu S, Al-Ahmed N, Dayem HA, Nanda A, Tawdy A, Alogayell L, Iraqi M, Abdul Hay N, El Enezi M, Walkhinde S, Kamal M, Aldhuhoori M, Almesfer A, Abd Elwhab A, Al Hawsawi KA, Barakat A, Chmayse S, Hafiz M, Chouikrat Z, Fahmy M.J Dermatolog Treat. 2025 Dec;36(1):2443110. https://pubmed.ncbi.nlm.nih.gov/39761970/

 

  1. Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis. Del Canto A, Cárcamo C, Garcia L, Aylwin E, Jürgensen-Heinrich L, Guzman-Carcamo I, de la Barra J, Gutierrez-Calquin L, Barrera-Hormazabal A, Cruz JP, Bravo S, Pelayo C, Soler B, Uribe-San-Martin R, Ciampi E. Mult Scler. 2025 Jan 6:13524585241309835. https://pubmed.ncbi.nlm.nih.gov/39757941/

 

  1. Real-world healthcare utilization and costs of peripheral nerve stimulation with a micro-IPG system. Kalia H, Thapa B, Staats P, Martin P, Stetter K, Feldman B, Marci C. Pain Manag. 2025 Jan 6:1-10. https://pubmed.ncbi.nlm.nih.gov/39757932/

 

  1. Hyperkalemia and the Risks of Adverse Cardiovascular Outcomes in Patients With Chronic Kidney Disease. Agiro A, Mu F, Cook E, Greatsinger A, Chen J, Zhao A, Louden E, Colman E, Desai P, Chertow GM.J Am Heart Assoc. 2025 Jan 7;14(1):e035256. https://pubmed.ncbi.nlm.nih.gov/39719421/

 

  1. Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database. Lindsay AC, Walker AM, Schneeweiss S. J Am Heart Assoc. 2025 Jan 7;14(1):e035689. https://pubmed.ncbi.nlm.nih.gov/39719418/

 

  1. The evidence base for rotavirus vaccination in India: Current status, future needs. Bhat N, Vodicka E, Clifford A, Ananth KB, Bavdekar A, Roy AD, Parashar U, Tate J, Haldar P, Kang G.Vaccine. 2025 Jan 12;44:126551. Review. https://pubmed.ncbi.nlm.nih.gov/39615343/

 

  1. Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study. de Lima EDS, Antunes MOB, de Souza JS, Jones MH, Stein RT, Pinto LA, Friedrich F, Scotta MC. Vaccine. 2025 Jan 12;44:126550. https://pubmed.ncbi.nlm.nih.gov/39603074/